ABOUT OFF-X


Unexpected toxicity and safety issues constitute one of the most disruptive events in drug R&D, with one third of drug attrition still directly related to these events. In this context, a translational approach to drug safety and prompt access to actionable safety intelligence can significantly reduce patient burden and avoid costly failures.

Since 2017, the OFF-XTM portal has been supporting translational researchers in pharmaceutical and healthcare organizations to de-risk drug R&D programs.

By delivering critical integrated preclinical toxicity and clinical adverse event intelligence coupled to advanced analytics, OFF-XTM allows safety liabilities to be monitored and anticipated across all phases of drug R&D and post-marketing

Rapid access to actionable safety intelligence via OFF-X provides a critical competitive advantage for your R&D:

Contact us today to arrange a demonstration and request a trial



https://clarivate.com/products/biopharma/discovery-clinical-regulatory/?lid=bioinfogate#howwehelp